Antares Pharma Inc

Type: Company
Name: Antares Pharma Inc
Nationality: United States
Web Address: http://www.antarespharma.com/
First reported 2 hours ago - Updated 1 hour ago - 5 reports

Antares Pharma to Host Third Quarter 2014 Operating and Financial Results Conference Call

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its third quarter 2014 financial results before the market opens on Thursday, November 6, 2014 and host a conference call…Click to Continue » ... [Published Fort Mills Times - 1 hour ago]
First reported Oct 29 2014 - Updated 2 hours ago - 1 reports

Antares Pharma has the Highest Revenue Per Employee in the Health Care Supplies Industry (AIS, VIVO, ELGX, CERS, OSUR)

(Comtex SmarTrend(R)) Below are the three companies in the Health Care Supplies industry with the highest Revenue Per Employee (RPE). Analysts use RPE as a measure to compare the productivity of companies in the same industry.Antares Pharma ranks highest ... [Published Individual.com - Oct 29 2014]
First reported Oct 27 2014 - Updated Oct 27 2014 - 1 reports

Antares Pharma : Patent Application Titled "Intradermal Injector" Published Online

By a News Reporter-Staff News Editor at Politics & Government Week -- According to news reporting originating from Washington, D.C. , by VerticalNews journalists, a patent application by the inventors SADOWSKI, Peter L. ( Woodbury, MN ); LESCH, JR., Paul ... [Published 4 Traders - Oct 27 2014]
First reported Oct 22 2014 - Updated Oct 22 2014 - 1 reports

Analysts’ New Coverage for October, 22nd (ATRS, BRGYY, CHSP, DTLK, ECA, FXCM, GPL, HF, IPXL, LHO)

Analysts’ new coverage for Wednesday, October 22nd: JMP Securities assumed coverage on shares of Antares Pharma (NASDAQ:ATRS). The firm issued an outperform rating and a $4.00 target price on the stock. Jefferies Group began coverage on shares of BG Group ... [Published Mideast Time - Oct 22 2014]
First reported Oct 22 2014 - Updated Oct 22 2014 - 1 reports

JMP Securities Initiates Coverage on Antares Pharma (ATRS)

JMP Securities began coverage on shares of Antares Pharma (NASDAQ:ATRS)Shares of Antares Pharma (NASDAQ:ATRS) traded up 2.50% on Wednesday, hitting $2.05. 594,439 shares of the company’s stock traded hands. Antares Pharma has a one year low of $1.82 and ... [Published American Banking News - Oct 22 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 2 reports

Advanced Cell Technology Appoints As SVP Of Business Development & Chief Commercial Officer

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced the appointment of LeRoux Jooste to the newly created position of Senior Vice President of Business Development and Chief Commercial Officer. ... [Published BioSpace - Oct 20 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

New commercial chief at Advanced Cell Tech

News EditorAdvanced Cell Technology (OTCQB:ACTC -1.8%) appoints LeRoux Jooste as SVP of Business Development and Chief Commercial Officer. He joins the firm from Antares Pharma where he was SVP and GM, Pharmaceuticals.Sent to 6,525 people who get email ... [Published Seeking Alpha - Oct 20 2014]
First reported Oct 12 2014 - Updated Oct 12 2014 - 2 reports

Update: Antares Pharma Looks To Improve Intellectual Property

By Mark Chapman :In a previous article , I indicated that the uncertainty of Antares Pharma (NASDAQ: ATRS ) intellectual property (IP) was a likely concern for many investors, thus aiding in the steep sell-off of the company's stock. The strength of Antares ... [Published BioPortfolio - Oct 12 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Advanced Cell Technology's Turnaround Has Near-Term Catalysts

By BiOCell :Advanced Cell Technology ( OTCQB:ACTC ) has made great strides, especially in the last several months. When Paul Wotton decided to leave a secure high paying CEO position at Antares Pharma to come aboard a financially strapped company with ... [Published BioPortfolio - Oct 07 2014]
First reported Sep 03 2014 - Updated Sep 04 2014 - 3 reports

Antares Pharma to Participate at the Morgan Stanley Healthcare Conference

EWING, N.J.--(EON: Enhanced Online News)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P. Hobbs, President and Chief Executive Officer and Robert F. Apple, Chief Financial Officer and President of the Parenteral Products Group, will ... [Published EON Science - Sep 03 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 3 reports

Antares Pharma to Host Second Quarter 2014 Operating and Financial Results Conference Call

EWING, N.J.--(EON: Enhanced Online News)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2014 financial results before the market opens on Thursday, August 7, 2014, and host a conference call shortly thereafter ... [Published EON Science - Jul 31 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 3 reports

Antares Pharma Announces First Patient Dosed in Phase 3 QuickShot Study Evaluating Testosterone-Deficient Adult Males

EWING, N.J.--(EON: Enhanced Online News)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the first patient has been dosed in a double-blind, multiple-dose, phase 3 study to evaluate the efficacy and safety of QuickShot® Testosterone (QS T) administered ... [Published EON Science - Jul 22 2014]

Quotes

...information on this patent application, VerticalNews editors also obtained the inventors' summary information for this patent application: "The invention relates to an injector, which is preferably an intradermal injection device. A preferred embodiment of the injector includes a chamber configured for containing a substance to be injected. A needle is operatively associated with the chamber and has a length sufficient to deliver the substance to an intradermal injection site. A collar surrounds the needle and defines collar cavity. The collar has a peripheral forward skin-contacting surface that surrounds and is radially spaced from the needle and injection site by an area that is sufficiently large to allow a patient's skin to move into the collar cavity to properly position the needle for intradermal delivery of the substance to the injection site and to allow spread of the injected substance at the injection site so as to inhibit or prevent backpressure causing the injected substance to flow out of the hole created in the skin by the needle after the injection. An energy source preferably is associated with the needle to assist in delivering the substance to the injection site. The preferred energy source is configured to provide an injection assisting pressure of between about 50 and 300 psi to the substance."
"LeRoux's appointment completes our senior management team and brings the 'voice of the customer' into our product development process. LeRoux has tremendous experience leading commercialization and partnering activities and is joining our company at the right time. We are about to initiate our phase 2 clinical studies with the RPE program and many of our pre-clinical programs have shown promising proof-of-concept data. As we continue to focus on regenerative ophthalmology, our non-ophthalmic programs enable us to seek collaborations with external groups that have the resources necessary to bring the results of our ground-breaking technologies to patients in need."
Original Article: NEXT ARTICLE More From BioPortfolio on "Comparative Analysis Reveals Undervalued Asset In Antares' Pipeline: First And Only Testosterone Auto-Injector"
...Antares hasn't given any guidance, but they stated "we believe that a once weekly, convenient, precise quick-to-administer subcutaneous dose of testosterone will become the choice route of administration" during their Q1-2014 conference call

More Content

All (66) | News (20) | Reports (0) | Blogs (41) | Audio/Video (0) | Fact Sheets (0) | Press Releases (5)
sort by: Date | Relevance
Antares Pharma to Host Third Quarter 2014 Opera... [Published Fort Mills Times - 1 hour ago]
Antares Pharma to Host Third Quarter 2014 Opera... [Published EON Science - 2 hours ago]
Antares Pharma to Host Third Quarter 2014 Opera... [Published BioPortfolio - 2 hours ago]
Antares Pharma to Host Third Quarter 2014 Opera... [Published Business Wire Science: Science News - 2 hours ago]
Antares Pharma to Host Third Quarter 2014 Opera... [Published Business Wire Health News - 2 hours ago]
Pre-Filled Syringes Market and Digital Syringe ... [Published Scottrade - 3 hours ago]
Antares Pharma has the Highest Revenue Per Empl... [Published Individual.com - Oct 29 2014]
Antares Pharma : Patent Application Titled "Int... [Published 4 Traders - Oct 27 2014]
Advanced Cell Technology Is Scaling Up Its Bloo... [Published Seeking Alpha - Oct 27 2014]
Analysts’ New Coverage for October, 22nd (ATRS,... [Published Mideast Time - Oct 22 2014]
JMP Securities Initiates Coverage on Antares Ph... [Published American Banking News - Oct 22 2014]
Needle-Free Delivery: Technology and Market For... [Published Scottrade - Oct 21 2014]
Advanced Cell Technology Appoints As SVP Of Bus... [Published BioSpace - Oct 20 2014]
New commercial chief at Advanced Cell Tech [Published Seeking Alpha - Oct 20 2014]
Advanced Cell Technology Appoints LeRoux Jooste... [Published Business Wire Health News - Oct 20 2014]
Update: Antares Pharma Looks To Improve Intelle... [Published BioPortfolio - Oct 12 2014]
Update: Antares Pharma Looks To Improve Intelle... [Published Seeking Alpha - Oct 12 2014]
Advanced Cell Technology's Turnaround Has Near-... [Published BioPortfolio - Oct 07 2014]
Comparative Analysis Reveals Undervalued Asset ... [Published BioPortfolio - Sep 30 2014]
Comparative Analysis Reveals Undervalued Asset ... [Published Seeking Alpha - Sep 29 2014]
Interesting ATRS Call Options For May 2015 [Published Chicago Daily Herald - Sep 24 2014]
Analysts View on Health Care Equipment and Supp... [Published Financial Services - Sep 24 2014]
Leasing of flex industrial space picks up locally [Published Finance & Commerce - Sep 24 2014]
Antares Pharma Announces Promotion of Robert F.... [Published Business Wire Health News - Sep 15 2014]
Antares Pharma to Participate at the Morgan Sta... [Published EON Science - Sep 03 2014]
Antares Pharma to Participate at the Morgan Sta... [Published Business Wire Science: Science News - Sep 03 2014]
Antares Pharma to Participate at the Morgan Sta... [Published Business Wire Health News - Sep 03 2014]
5 Breakout Stocks Under $10 Set to Soar [Published The Street Latest - Aug 28 2014]
Health Care Equipment and Supplies Equities Scr... [Published Financial Services - Aug 18 2014]
Global Transdermal Drug Delivery Market 2014-20... [Published PR Newswire: General Business - Aug 07 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Antares Pharma to Host Third Quarter 2014 Opera... [Published EON Science - 2 hours ago]
EWING, N.J.--(EON: Enhanced Online News)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its third quarter 2014 financial results before the market opens on Thursday, November 6, 2014 and host a conference call at 8:30 a.m. ET (Eastern ...
Antares Pharma to Host Third Quarter 2014 Opera... [Published Business Wire Science: Science News - 2 hours ago]
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its third quarter 2014 financial results before the market opens on Thursday, November 6, 2014 and host a conference call at 8:30 a.m. ET (Eastern Time) ...
Antares Pharma to Host Third Quarter 2014 Opera... [Published Business Wire Health News - 2 hours ago]
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its third quarter 2014 financial results before the market opens on Thursday, November 6, 2014 and host a conference call at 8:30 a.m. ET (Eastern Time) ...
Advanced Cell Technology Appoints LeRoux Jooste... [Published Business Wire Health News - Oct 20 2014]
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced the appointment of LeRoux Jooste to the newly created position of Senior Vice President of Business ...
Antares Pharma Announces Promotion of Robert F.... [Published Business Wire Health News - Sep 15 2014]
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple has been promoted to Chief Operating Officer effective immediately. The Company also announced that a retained search has begun to fill the position ...
1 2 3 4 5 6 7 8 9

Press Releases

sort by: Date | Relevance
Analysts View on Health Care Equipment and Supp... [Published Financial Services - Sep 24 2014]
Health Care Equipment and Supplies Equities Scr... [Published Financial Services - Aug 18 2014]
Global Transdermal Drug Delivery Market 2014-20... [Published GlobeNewswire: Advertising News - Aug 06 2014]
Pre-Market Pulse on Health Care Stocks -- Resea... [Published Financial Services - Jul 10 2014]
Pre-market Equity Watch on Health Care Equipmen... [Published Financial Services - Jun 19 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.